Male breast cancer: A retrospective study comparing survival with female breast cancer

Baojiang,Li; Tingting,Liu; Gang,Li; Li,Zhang

doi:10.3892/ol.2012.809

Male breast cancer: A retrospective study comparing survival with female breast cancer

Authors:
- Li Baojiang
- Liu Tingting
- Li Gang
- Zhang Li
View Affiliations

Affiliations: Department of Breast Oncology, The Central Hospital of Tai'an, Tai'an, Shandong 271000, P.R. China, Department of Vascular Surgery, The Central Hospital of Tai'an, Tai'an, Shandong 271000, P.R. China, Department of Breast Oncology, Key Laboratory of Breast Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, Ministry of Education, Tianjin 300060, P.R. China
Published online on: July 18, 2012 https://doi.org/10.3892/ol.2012.809
Pages: 642-646

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Male breast cancer is a rare disease. The aim of this study was to compare overall survival (OS) and disease‑free survival (DFS) in a group of matched males and females with breast cancer. The clinical data and survival status of 42 operable male breast cancer (MBC) cases treated at the Central Hospital of Tai'an from 1982 to 2006 were collected. Each MBC patient recorded in the database was matched with two female breast cancer (FBC) patients. Matching was conducted based on age, year of diagnosis, stage and pathology. SPSS 16.0 software was used for statistical analysis. The Chi‑square test was used for the categorical data, the Kaplan‑Meier method was applied to analyze survival and the log‑rank test was used to compare curves between the groups. P<0.05 was considered to indicate a statistically significant difference. The 42 MBC patients were matched with 84 FBC patients. The mean age at diagnosis was 58.0±11.3 years for males and 57.1±10.6 years for females, and the median follow‑up time was 64 months (range, 5-262 months) for males and 71 months (range, 29-283 months) for females. Significant differences were identified for tumor location, hormone receptor status, adjuvant chemotherapy and hormone therapy between the two groups. Monofactorial analysis demonstrated that tumor size, lymph node status and AJCC stage were prognostic factors in MBC patients. The 5‑ and 10‑year DFS rates were 61.2 and 40.7% for males, and 68.7 and 43.0% for females, respectively. The 5- and 10-year OS rates were 75.3 and 52.3% for males, and 82.9 and 63.2% for females, respectively. In our study, male breast carcinoma patients had a worse prognosis compared to female breast carcinoma patients which may be due to the deficiency of adjuvant chemotherapy and endocrine therapy.

View Figures

View References

1.	A JemalR SiegelE WardCancer statistics, 2008CA Cancer J Clin587196200810.3322/CA.2007.0010
2.	SH GiordanoMale breast cancer: it's time for evidence instead of extrapolationOnkologie315055062008
3.	KA RosenblattDB ThomasA McTiernanBreast cancer in men: aspects of familial aggregationJ Natl Cancer Inst83849854199110.1093/jnci/83.12.8492061945
4.	F MarchalM SalouC MarchalMen with breast cancer have same disease-specific and event-free survival as womenAnn Surg Oncol16972978200910.1245/s10434-009-0327-619184227
5.	K LynnRare male breast cancer has similarities to female diseaseMLO Med Lab Obs423436201021213581
6.	L NeumayerTL SchifftnerWG HendersonBreast cancer surgery in Veterans Affairs and selected university medical centers: results of the patient safety in surgery studyJ Am Coll Surg20412351241200710.1016/j.jamcollsurg.2007.03.018
7.	K AnanS MitsuyamaK NishiharaBreast cancer in Japanese men: does sex affect prognosis?Breast Cancer11180186200410.1007/BF0296829915550865
8.	JJ ShusterMedian follow-up in clinical trialsJ Clin Oncol919119219911985169
9.	EL KaplanP MeierNonparametric estimation from incomplete observationsJ Am Statist Assoc53457481195810.1080/01621459.1958.10501452
10.	SH GiordanoDS CohenAU BuzdarBreast carcinoma in men: a population-based studyCancer1015157200410.1002/cncr.2031215221988
11.	MG JoshiAK LeeM LodaMale breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcomeCancer77490498199610.1002/(SICI)1097-0142(19960201)77:3%3C490::AID-CNCR10%3E3.0.CO;2-%238630956
12.	PC WillsherIH LeachIO EllisA comparison outcome of male breast cancer with female breast cancerAm J Surg173185188199710.1016/S0002-9610(97)89592-X9124623
13.	MB El-TamerIK KomenakaA TroxelMen with breast cancer have better disease-specific survival than womenArch Surg13910791082200410.1001/archsurg.139.10.107915492147
14.	WF AndersonMD AlthuisLA BrintonSS DevesaIs male breast cancer similar or different than female breast cancer?Breast Cancer Res Treat837786200410.1023/B:BREA.0000010701.08825.2d14997057
15.	C RudlowskiN FriedrichsA FaridiHer-2/neu gene amplification and protein expression in primary male breast cancerBreast Cancer Res Treat84215223200410.1023/B:BREA.0000019953.92921.7e15026619
16.	DG TiezziJM AndradeA Ribeiro-SilvaHER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combinationBMC Cancer736200710.1186/1471-2407-7-36
17.	JM BentelSN BirrellMA PicheringAndrogen receptor agonist activity of the synthetic progestin, medroxyprogesterone acetate, in human breast cancer cellsMol Cell Endocrinol1541120199910.1016/S0303-7207(99)00109-4
18.	A AuvinenRE CurtisE RonRisk of subsequent cancer following breast cancer in menJ Natl Cancer Inst9413301332200210.1093/jnci/94.17.133012208898
19.	C DongK HemminkiSecond primary breast cancer in menBreast Cancer Res Treat66171172200110.1023/A:101063942920711437104
20.	NC HodgsonJH ButtonD FranceschiMale breast cancer: is the incidence increasing?Ann Surg Oncol11751755200410.1245/ASO.2004.01.00115289238
21.	K HemminkiG SceloP BoffettaSencond primary malignancies in patients with male breast cancerBr J Cancer9212881292200510.1038/sj.bjc.660250515798766
22.	SB LeibowitzJE GarberEA FoxMale patients with diagnoses of both breast cancer and prostate cancerBreast J9208212200310.1046/j.1524-4741.2003.09312.x12752629
23.	S Satram-HoangA ZiogasH Anton-CulverRisk of second primary cancer in men with breast cancerBreast Cancer Res9R10200710.1186/bcr164317254323
24.	National Comprehensive Cancer NetworkNCCN practice guidelines in oncology 2009Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 30 May, 2010
25.	SH GiordanoAU BuzdarGN HortobagyiBreast cancer in menAnn Intern Med137678687200210.7326/0003-4819-137-8-200210150-0001312379069
26.	SH GiordanoGH PerkinsK BroglioAdjuvant systemic therapy for male breast carcinomaCancer10423592364200510.1002/cncr.2152616270318
27.	A AgrawalAA AyantundeR RampaulJF RobertsonMale breast cancer: a review of clinical managementBreast Cancer Res Treat1031121200710.1007/s10549-006-9356-z
28.	Z NahlehS GirniusMale breast cancer: a gender issueNat Clin Pract Oncol3428437200610.1038/ncponc0564
29.	IS FentimanA FourquetGN HortobagyiMale breast cancerLancet367595604200610.1016/S0140-6736(06)68226-3
30.	A MariottoEJ FeuerLC HarlanTrends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999J Natl Cancer Inst94162616342003
31.	G RibeiroR SwindellAdjuvant tamoxifen for male breast cancer (MBC)Br J Cancer65252254199210.1038/bjc.1992.501739625
32.	TF AnelliA AnelliKN TranTamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patientsCancer747477199410.1002/1097-0142(19940701)74:1%3C74::AID-CNCR2820740113%3E3.0.CO;2-%238004585